192 related articles for article (PubMed ID: 9166938)
1. Clinical evaluation of urinary transforming growth factor-beta1 and serum alpha-fetoprotein as tumour markers of hepatocellular carcinoma.
Tsai JF; Jeng JE; Chuang LY; Yang ML; Ho MS; Chang WY; Hsieh MY; Lin ZY; Tsai JH
Br J Cancer; 1997; 75(10):1460-6. PubMed ID: 9166938
[TBL] [Abstract][Full Text] [Related]
2. Elevated urinary transforming growth factor-beta1 level as a tumour marker and predictor of poor survival in cirrhotic hepatocellular carcinoma.
Tsai JF; Jeng JE; Chuang LY; Yang ML; Ho MS; Chang WY; Hsieh MY; Lin ZY; Tsai JH
Br J Cancer; 1997; 76(2):244-50. PubMed ID: 9231926
[TBL] [Abstract][Full Text] [Related]
3. Urinary transforming growth factor α and serum α-fetoprotein as tumor markers of hepatocellular carcinoma.
Jeng JE; Tsai MF; Tsai HR; Chuang LY; Lin ZY; Hsieh MY; Chen SC; Chuang WL; Wang LY; Yu ML; Dai CY; Tsai JF
Tumour Biol; 2014 Apr; 35(4):3689-98. PubMed ID: 24375326
[TBL] [Abstract][Full Text] [Related]
4. Clinical evaluation of serum alpha-fetoprotein and circulating immune complexes as tumour markers of hepatocellular carcinoma.
Tsai JF; Jeng JE; Ho MS; Chang WY; Lin ZY; Tsai JH
Br J Cancer; 1995 Aug; 72(2):442-6. PubMed ID: 7543774
[TBL] [Abstract][Full Text] [Related]
5. Clinical relevance of transforming growth factor-beta 1 in the urine of patients with hepatocellular carcinoma.
Tsai JF; Chuang LY; Jeng JE; Yang ML; Chang WY; Hsieh MY; Lin ZY; Tsai JH
Medicine (Baltimore); 1997 May; 76(3):213-26. PubMed ID: 9193456
[TBL] [Abstract][Full Text] [Related]
6. Serum insulin-like growth factor-II and alpha-fetoprotein as tumor markers of hepatocellular carcinoma.
Tsai JF; Jeng JE; Chuang LY; You HL; Ho MS; Lai CS; Wang LY; Hsieh MY; Chen SC; Chuang WL; Lin ZY; Yu ML; Dai CY
Tumour Biol; 2003; 24(6):291-8. PubMed ID: 15004489
[TBL] [Abstract][Full Text] [Related]
7. Urinary transforming growth factor-beta 1 in relation to serum alpha-fetoprotein in hepatocellular carcinoma.
Tsai JF; Jeng JE; Chuang LY; Chang WY; Hsieh MY; Lin ZY; Tsai JH
Scand J Gastroenterol; 1997 Mar; 32(3):254-60. PubMed ID: 9085463
[TBL] [Abstract][Full Text] [Related]
8. Transforming growth factor beta1 and soluble Fas serum levels in hepatocellular carcinoma.
Sacco R; Leuci D; Tortorella C; Fiore G; Marinosci F; Schiraldi O; Antonaci S
Cytokine; 2000 Jun; 12(6):811-4. PubMed ID: 10843770
[TBL] [Abstract][Full Text] [Related]
9. Serum insulin-like growth factor-II as a serologic marker of small hepatocellular carcinoma.
Tsai JF; Jeng JE; Chuang LY; You HL; Wang LY; Hsieh MY; Chen SC; Chuang WL; Lin ZY; Yu ML; Dai CY
Scand J Gastroenterol; 2005 Jan; 40(1):68-75. PubMed ID: 15841717
[TBL] [Abstract][Full Text] [Related]
10. Transforming growth factor-β1 gene expression in hepatocellular carcinoma: a preliminary report.
Farid IM; Hamza IM; El-Abd DM; Mohyi AM; AbdulLatif MM; Aref AT; Hamza DM
Arab J Gastroenterol; 2014; 15(3-4):142-7. PubMed ID: 25475758
[TBL] [Abstract][Full Text] [Related]
11. Serological biomarkers of hepatocellular carcinoma in Egyptian patients.
El-Tayeh SF; Hussein TD; El-Houseini ME; Amer MA; El-Sherbini M; Elshemey WM
Dis Markers; 2012; 32(4):255-63. PubMed ID: 22430192
[TBL] [Abstract][Full Text] [Related]
12. Transforming growth factor-beta1 as a useful serologic marker of small hepatocellular carcinoma.
Song BC; Chung YH; Kim JA; Choi WB; Suh DD; Pyo SI; Shin JW; Lee HC; Lee YS; Suh DJ
Cancer; 2002 Jan; 94(1):175-80. PubMed ID: 11815974
[TBL] [Abstract][Full Text] [Related]
13. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients.
Lim TS; Kim DY; Han KH; Kim HS; Shin SH; Jung KS; Kim BK; Kim SU; Park JY; Ahn SH
Scand J Gastroenterol; 2016 Mar; 51(3):344-53. PubMed ID: 26340708
[TBL] [Abstract][Full Text] [Related]
14. The Bcl-2 and TGF-beta1 levels in patients with chronic hepatitis C, liver cirrhosis and hepatocellular carcinoma.
Ali MA; Koura BA; el-Mashad N; Zaghloul MH
Egypt J Immunol; 2004; 11(1):83-90. PubMed ID: 15724390
[TBL] [Abstract][Full Text] [Related]
15. Preoperative serum α-fetoprotein and prognosis after hepatectomy for hepatocellular carcinoma.
Yang SL; Liu LP; Yang S; Liu L; Ren JW; Fang X; Chen GG; Lai PB
Br J Surg; 2016 May; 103(6):716-724. PubMed ID: 26996727
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic value of alpha-1-fetoprotein (AFP) as a biomarker for hepatocellular carcinoma recurrence after liver transplantation.
Nörthen A; Asendorf T; Walson PD; Oellerich M
Clin Biochem; 2018 Feb; 52():20-25. PubMed ID: 29054441
[TBL] [Abstract][Full Text] [Related]
17. Clinical evaluation of pancreatitis-associated protein as a serum marker of hepatocellular carcinoma: comparison with alpha-fetoprotein.
Montalto G; Iovanna JL; Soresi M; Dusetti N; Carroccio A; Barthelemy-Bialas S; Cartabellotta A; Dagorn JC
Oncology; 1998; 55(5):421-5. PubMed ID: 9732219
[TBL] [Abstract][Full Text] [Related]
18. Elevation of transforming growth factor alpha and its relationship to the epidermal growth factor and alpha-fetoprotein levels in patients with hepatocellular carcinoma.
Yeh YC; Tsai JF; Chuang LY; Yeh HW; Tsai JH; Florine DL; Tam JP
Cancer Res; 1987 Feb; 47(3):896-901. PubMed ID: 2433030
[TBL] [Abstract][Full Text] [Related]
19. Feasibility of α-fetoprotein as a diagnostic tool for hepatocellular carcinoma in Korea.
Ahn DG; Kim HJ; Kang H; Lee HW; Bae SH; Lee JH; Paik YH; Lee JS
Korean J Intern Med; 2016 Jan; 31(1):46-53. PubMed ID: 26767857
[TBL] [Abstract][Full Text] [Related]
20. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
